Synergistic effect of temozolomide and thymoquinone on human glioblastoma multiforme cell line (U87MG) | Zendy

Mona Pazhouhi | Zendy; Reyhaneh Sariri | Zendy; Mohammad Rasool Khazaei | Zendy; MohammadTaher Moradi | Zendy; Mozafar Khazaei | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Synergistic effect of temozolomide and thymoquinone on human glioblastoma multiforme cell line (U87MG)

Author(s) -

Mona Pazhouhi,

Reyhaneh Sariri,

Mohammad Rasool Khazaei,

MohammadTaher Moradi,

Mozafar Khazaei

Publication year - 2018

Publication title -

journal of cancer research and therapeutics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.475

H-Index - 39

eISSN - 0973-1482

pISSN - 1998-4138

DOI - 10.4103/0973-1482.187241

Subject(s) - temozolomide , thymoquinone , cancer research , chemistry , lactate dehydrogenase , viability assay , cell culture , matrix metalloproteinase , cytotoxicity , pharmacology , cell , medicine , glioblastoma , biology , in vitro , enzyme , biochemistry , genetics , antioxidant

Temozolomide (TMZ) is an alkylating agent used for glioblastoma multiforme (GBM) treatment. Nevertheless, resistance to TMZ is a major obstacle to successful treatment of this cancer. The aim of the present study was to investigate the effects of TMZ and thymoquinone (TQ) on U87MG cell line.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research